Publications by authors named "Mafalda Oliveira"

35Publications

Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al.

J Clin Oncol 2021 Jan 17;39(3):254-255. Epub 2020 Dec 17.

Cristina Saura, MD, PhD and Mafalda Oliveira, MD, PhD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), SOLTI Breast Cancer Cooperative Group, Barcelona, Spain; Sung-Bae Kim, MD, PhD, University of Ulsan College of Medicine, Seoul, Republic of Korea; Thomas Yau, MD, MBBS, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China, Toshimi Takano, MD, Toranomon Hospital, Tokyo, Japan; and Adam Brufsky, MD, PhD, Magee-Womens Hospital of UPMC, Pittsburgh, PA.

View Article and Find Full Text PDF
January 2021

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER Breast Cancer.

Cancer Cell 2020 Oct 24;38(4):516-533.e9. Epub 2020 Sep 24.

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK; Department of Biochemistry, University of Cambridge, Cambridge UK. Electronic address:

View Article and Find Full Text PDF
October 2020

Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.

Expert Rev Anticancer Ther 2020 Sep 30;20(9):731-741. Epub 2020 Aug 30.

Medical Oncology Department, Vall d'Hebron Hospital , Barcelona, Spain.

View Article and Find Full Text PDF
September 2020

Tackling the Biological Diversity in Early Triple-Negative Breast Cancer.

Breast Care (Basel) 2020 Jun 9;15(3):205-207. Epub 2020 Jun 9.

Department of Medical Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

View Article and Find Full Text PDF
June 2020

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

N Engl J Med 2020 02 11;382(7):597-609. Epub 2019 Dec 11.

From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) - both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology-Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H., D.S.), and Stanford Comprehensive Cancer Institute, Palo Alto (M.P.) - both in California; Dana-Farber Cancer Institute, Boston (N.U.L., I.K., E.P.W.); University of Colorado Cancer Center, Aurora (V.B.); Duke Cancer Institute, Durham (C.A.), and University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (L.A.C.) - both in North Carolina; University Health Network, Princess Margaret Cancer Centre, Toronto (P.L.B.), and British Columbia Cancer, Vancouver (K.G.) - both in Canada; Hospital Universitario Vall D'Hebron, Barcelona (M.O.); Sygehus Lillebaelt-Vejle Sygehus, Vejle, Denmark (E.J.); Centre Léon Bérard, Lyon, France (T.B.); Rambam Health Care Campus, Haifa, Israel (S.S.S.); Universitaetsklinikum Hamburg-Eppendorf, Hamburg (V.M.), and German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Hospital Cuf Descobertas R. Mário Botas, Lisbon, Portugal (S.B.); Cliniques Universitaires Saint-Luc, Brussels (F.P.D.); Third Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, and Cancer Cluster Salzburg, Salzburg, Austria (R.G.); Istituto Europeo di Oncologia, IRCCS, University of Milan, Milan (G.C.); and Seattle Genetics, Bothell, WA (M.C.P.-W., L.W., W.F.).

View Article and Find Full Text PDF
February 2020